These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27899215)

  • 21. Use of new psychoactive substances to mimic prescription drugs: The trend in France.
    Batisse A; Eiden C; Peyriere H; Djezzar S;
    Neurotoxicology; 2020 Jul; 79():20-24. PubMed ID: 32240674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Synthetic Drugs - An Overview of Important and Newly Emerging Substances].
    Betzler F; Heinz A; Köhler S
    Fortschr Neurol Psychiatr; 2016 Nov; 84(11):690-698. PubMed ID: 27846654
    [No Abstract]   [Full Text] [Related]  

  • 24. Femoral blood concentrations of flualprazolam in 33 postmortem cases.
    Kriikku P; Rasanen I; Ojanperä I; Thelander G; Kronstrand R; Vikingsson S
    Forensic Sci Int; 2020 Feb; 307():110101. PubMed ID: 31865266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
    Wood DM; Sedefov R; Cunningham A; Dargan PI
    Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
    Scherbaum N; Schifano F; Bonnet U
    Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel psychoactive substances.
    Krabseth HM; Tuv SS; Strand MC; Karinen RA; Wiik E; Vevelstad MS; Westin AA; Øiestad EL; Vindenes V
    Tidsskr Nor Laegeforen; 2016 May; 136(8):714-7. PubMed ID: 27143461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A literature review of blood concentrations of new psychoactive substances classified as phenethylamines, aminoindanes, arylalkylamines, arylcyclohexylamines, and indolalkylamines.
    Karinen R; Høiseth G
    Forensic Sci Int; 2017 Jul; 276():120-125. PubMed ID: 28527345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deconstructing Designer Drugs.
    Sellers EM
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
    Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WHO Expert Committee on Drug Dependence.
    World Health Organization
    World Health Organ Tech Rep Ser; 2016; (998):1-34. PubMed ID: 29144065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN).
    Dines AM; Wood DM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Sedefov R; Dargan PI;
    Clin Toxicol (Phila); 2015 Nov; 53(9):893-900. PubMed ID: 26503789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.
    Morgan CJ; Noronha LA; Muetzelfeldt M; Feilding A; Curran HV
    J Psychopharmacol; 2013 Jun; 27(6):497-506. PubMed ID: 23438502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Staphylococcus aureus bacteraemia associated with injected new psychoactive substances.
    Griffith DJ; Mackintosh CL; Inverarity D
    Epidemiol Infect; 2016 Apr; 144(6):1257-66. PubMed ID: 26548371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recreational drugs: the complication's pleasure?].
    Joye F; Donzé N; Frochaux V; Niquille M; Selz Amaudruz F
    Rev Med Suisse; 2013 Aug; 9(394):1454-60. PubMed ID: 24024389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence of the use of designer drugs in Poland--review of the published evidence.
    Kryska S
    Przegl Epidemiol; 2016; 70(1):35-9, 121-3. PubMed ID: 27344472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
    Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
    Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.